| Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label … A Gronchi, S Ferrari, V Quagliuolo, JM Broto, AL Pousa, G Grignani, ... The Lancet Oncology 18 (6), 812-822, 2017 | 453 | 2017 |
| Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial G Grignani, E Palmerini, V Ferraresi, L D'Ambrosio, R Bertulli, SD Asaftei, ... The lancet oncology 16 (1), 98-107, 2015 | 326 | 2015 |
| Photoreduction of the fluorescent dye 2′-7′-dichlorofluorescein: a spin trapping and direct electron spin resonance study with implications for oxidative stress measurements E Marchesi, C Rota, YC Fann, CF Chignell, RP Mason Free Radical Biology and Medicine 26 (1-2), 148-161, 1999 | 202 | 1999 |
| Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: final results of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups A Gronchi, E Palmerini, V Quagliuolo, J Martin Broto, A Lopez Pousa, ... Journal of Clinical Oncology 38 (19), 2178-2186, 2020 | 176 | 2020 |
| Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): for how long? E Palmerini, NS Chawla, S Ferrari, M Sudan, P Picci, E Marchesi, ... European Journal of Cancer 76, 118-124, 2017 | 142 | 2017 |
| The nature of prooxidant activity of vitamin C M Paolini, L Pozzetti, GF Pedulli, E Marchesi, G Cantelli-Forti Life Sciences 64 (23), PL273-PL278, 1999 | 141 | 1999 |
| Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone E Palmerini, RL Jones, E Marchesi, A Paioli, M Cesari, A Longhi, ... BMC cancer 16, 1-8, 2016 | 92 | 2016 |
| Homolytic reactivity of group 14 organometallic hydrides toward nitroxides M Lucarini, E Marchesi, GF Pedulli, C Chatgilialoglu The Journal of Organic Chemistry 63 (5), 1687-1693, 1998 | 87 | 1998 |
| Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group G Grignani, L D'Ambrosio, Y Pignochino, E Palmerini, M Zucchetti, ... The Lancet Oncology 19 (10), 1360-1371, 2018 | 74 | 2018 |
| The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas E Palmerini, M Colangeli, C Nanni, S Fanti, E Marchesi, A Paioli, P Picci, ... European Journal of Nuclear Medicine and Molecular Imaging 44, 215-223, 2017 | 66 | 2017 |
| Neoadjuvant chemotherapy in high‐risk soft tissue sarcomas: a Sarculator‐based risk stratification analysis of the ISG‐STS 1001 randomized trial S Pasquali, E Palmerini, V Quagliuolo, J Martin‐Broto, A Lopez‐Pousa, ... Cancer 128 (1), 85-93, 2022 | 53 | 2022 |
| Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients E Palmerini, RL Jones, E Setola, P Picci, E Marchesi, R Luksch, ... Acta Oncologica 57 (7), 958-964, 2018 | 50 | 2018 |
| Primary angiosarcoma of bone: a retrospective analysis of 60 patients from 2 institutions E Palmerini, RG Maki, EL Staals, M Alberghini, CR Antonescu, C Ferrari, ... American journal of clinical oncology 37 (6), 528-534, 2014 | 42 | 2014 |
| Medium effects on the antioxidant activity of dipyridamole GF Pedulli, M Lucarini, E Marchesi, F Paolucci, S Roffia, D Fiorentini, ... Free Radical Biology and Medicine 26 (3-4), 295-302, 1999 | 38 | 1999 |
| sarcoma Full-dose neoadjuvant anthracycline+ ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk … A Gronchi, S Ferrari, V Quagliuolo, JM Broto, A Lopez-Pousa, G Grignani, ... Annals of Oncology 27, vi587, 2016 | 36 | 2016 |
| High dose ifosfamide in relapsed and unresectable high-grade osteosarcoma patients: a retrospective series E Palmerini, E Setola, G Grignani, L D’Ambrosio, A Comandone, A Righi, ... Cells 9 (11), 2389, 2020 | 32 | 2020 |
| IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib plus nivolumab in advanced soft tissue and bone sarcomas: Results of … JM Broto, N Hindi, GE Grignani, JM Trufero, A Redondo, C Valverde, ... Annals of Oncology 30, v684, 2019 | 25* | 2019 |
| Pharmacokinetics, safety, and activity of trabectedin as first‐line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard … F Grosso, L D’Ambrosio, M Zucchetti, T Ibrahim, S Tamberi, C Matteo, ... Cancer 126 (21), 4726-4734, 2020 | 24 | 2020 |
| Osteosarcoma follow-up: chest X-ray or computed tomography? A Paioli, M Rocca, L Cevolani, E Rimondi, D Vanel, E Palmerini, M Cesari, ... Clinical sarcoma research 7, 1-8, 2017 | 23 | 2017 |
| Taking EPR" snapshots" of the oxidative stress status in human blood M Paolini, L Valgimigli, E Marchesi, S Trespidi, GF Pedulli Free radical research 37 (5), 503-508, 2003 | 23 | 2003 |
